In achieving its enrolment target in November 2021, an important milestone has been reached by the Phase III PLX-PAD study.
HIPGEN - Cell Therapy for Improving Patient Mobility after Hip Fracture Arthroplasty - is a Phase III, multicenter, randomized, double-blind, placebo-controlled trial, designed to determine the efficacy, safety and tolerability of intramuscular injections of allogeneic placenta-expanded adherent stromal (PLX-PAD) cells for improved recovery following arthroplasty for hip fracture.
Rising healthcare costs and aging demographic changes present an opportunity for allogenic, placenta-cell-derived products to satisfy unmet clinical needs in the area of muscle regeneration following hip arthroplasty. The potential improvement of physical function following this common procedure could redefine the current standard of care and improve patients' lives.
Topline results are expected to be available in the third calendar quarter of 2022.
The HIPGEN study has received funding from the European Union’s Horizon 2020 research and innovation programme (grant agreement No 779293) and includes a network of 10 partners from eight countries, including the International Osteoporosis Foundation (IOF) as a communications partner.
The HIPGEN Fourth Annual Meeting for network partners will be held in Brussels, Belgium on 1 March 2022. IOF looks forward to presenting ongoing information about the novel trial throughout 2022.
For further information about the trial, visit the HIPGEN website